It has been previously shown that the treatment with the two protease inhibitors APG12 and APG19 confers protection in a rat model of mucosal candidiasis; in this study, we examined whether these peptidomimetic inhibitors are also effective as a cream formulation in reducing Candida albicans vaginal infection.
De Bernardis, F., Arancia, S., Tringali, G., Greco, M. C., Ragazzoni, E., Calugi, C., Trabocchi, A., Sandini, S., Graziani, S., Cauda, R., Cassone, A., Guarna, A., Navarra, P., Evaluation of efficacy, pharmacokinetics and tolerability of peptidomimetic aspartic proteinase inhibitors as cream formulation in experimental vaginal candidiasis, <<JOURNAL OF PHARMACY AND PHARMACOLOGY>>, 2014; (Agosto): 1094-1101. [doi:10.1111/jphp.12240] [http://hdl.handle.net/10807/60688]
Evaluation of efficacy, pharmacokinetics and tolerability of peptidomimetic aspartic proteinase inhibitors as cream formulation in experimental vaginal candidiasis
Arancia, Silvia;Tringali, Giuseppe;Greco, Maria Cristina;Ragazzoni, Enzo;Cauda, Roberto;Navarra, Pierluigi
2014
Abstract
It has been previously shown that the treatment with the two protease inhibitors APG12 and APG19 confers protection in a rat model of mucosal candidiasis; in this study, we examined whether these peptidomimetic inhibitors are also effective as a cream formulation in reducing Candida albicans vaginal infection.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
